ReviewCurrent oncology reports2011
Systemic therapy options for unresectable and metastatic chordomas.
Review in Current oncology reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 56 citations in OpenAlex.
- Analysis of long-term TNF-alpha induced EGFR tyrosine kinase inhibitor resistance in chordoma.RSC medicinal chemistry · 2025Article
- Population-based survival analysis of primary spinal chordoma in the US from 2000 to 2020.Journal of neuro-oncology · 2024Article
- Role of immunotherapy in treatment refractory chordomas: review of current evidence.Frontiers in surgery · 2024Review
- Activity of pemetrexed in pre-clinical chordoma models and humans.Scientific reports · 2023Article
- Incidence, Management, and Outcomes of Adult Spinal Chordoma Patients in the United States.Global spine journal · 2023Article
- Advancement of PI3 Kinase Inhibitor Combination Therapies for PI3K-Aberrant Chordoma.Journal of neurological surgery. Part B, Skull base · 2022Article
- Indolent multicentric chordoma - A previously undescribed entity: A Case report and literature review.Surgical neurology international · 2022Article
- CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway.Cancer cell international · 2021Article
- Characteristics and overall survival in pediatric versus adult skull base chordoma: a population-based study.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021Article
- Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review.Frontiers in immunology · 2021Review
- Translational Windows in Chordoma: A Target Appraisal.Frontiers in neurology · 2020Review
- Clinicopathologic characteristics of poorly differentiated chordoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- A historical recount of chordoma.Journal of neurosurgery. Spine · 2018Article
- STAT3 Inhibition as a Therapeutic Strategy for Chordoma.Journal of neurological surgery. Part B, Skull base · 2016Article
- Immunotherapy as a Potential Treatment for Chordoma: a Review.Current oncology reports · 2016Review
- Metastatic Chordoma: Report of the Two Cases and Review of the Literature.The Eurasian journal of medicine · 2015Article
- Primary sacrococcygeal chordoma with unusual skeletal muscle metastasis.Radiology case reports · 2014Article
- Carbon ion beam radiotherapy for sinonasal malignant tumors invading skull base.Case reports in otolaryngology · 2014Article
- A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology.PloS one · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chordoma is an exceedingly rare tumor, marked by a slow growth rate. Surgery is the treatment of choice, but the most frequent sites of origin (spine and skull base) make treatment of primary disease challenging. Local relapses affect more than 50% of cases, with a minority of patients being cured by further surgery. Furthermore, metastases occur in at least 20% of patients. For residual or recurrent disease, high-dose radiation therapy may be indicated. Radiation therapy is currently the preferred local treatment when surgery is problematic, exploiting most recent techniques, including proton beams and carbon ions. However, systemic therapy is needed in patients non-amenable to surgery and/or radiation therapy. We reviewed systemic treatments currently available, and targets possibly druggable in the future in this orphan disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.